Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fernando Souza-Fonseca-Guimaraes is active.

Publication


Featured researches published by Fernando Souza-Fonseca-Guimaraes.


Nature Immunology | 2014

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

Christopher J. Chan; Ludovic Martinet; Susan Gilfillan; Fernando Souza-Fonseca-Guimaraes; Melvyn T. Chow; Liam Town; David Ritchie; Marco Colonna; Daniel M. Andrews; Mark J. Smyth

CD96, CD226 (DNAM-1) and TIGIT belong to an emerging family of receptors that interact with nectin and nectin-like proteins. CD226 activates natural killer (NK) cell–mediated cytotoxicity, whereas TIGIT reportedly counterbalances CD226. In contrast, the role of CD96, which shares the ligand CD155 with CD226 and TIGIT, has remained unclear. In this study we found that CD96 competed with CD226 for CD155 binding and limited NK cell function by direct inhibition. As a result, Cd96−/− mice displayed hyperinflammatory responses to the bacterial product lipopolysaccharide (LPS) and resistance to carcinogenesis and experimental lung metastases. Our data provide the first description, to our knowledge, of the ability of CD96 to negatively control cytokine responses by NK cells. Blocking CD96 may have applications in pathologies in which NK cells are important.


Nature Immunology | 2017

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Yulong Gao; Fernando Souza-Fonseca-Guimaraes; Tobias Bald; Susanna S. Ng; Arabella Young; Shin Foong Ngiow; Jai Rautela; Jasmin Straube; Nic Waddell; Stephen J. Blake; Juming Yan; Laurent Bartholin; Jason S. Lee; Eric Vivier; Kazuyoshi Takeda; Meriem Messaoudene; Laurence Zitvogel; Michele W.L. Teng; Gabrielle T. Belz; Christian R. Engwerda; Nicholas D. Huntington; Kyohei Nakamura; Michael Hölzel; Mark J. Smyth

Avoiding destruction by immune cells is a hallmark of cancer, yet how tumors ultimately evade control by natural killer (NK) cells remains incompletely defined. Using global transcriptomic and flow-cytometry analyses and genetically engineered mouse models, we identified the cytokine-TGF-β-signaling-dependent conversion of NK cells (CD49a−CD49b+Eomes+) into intermediate type 1 innate lymphoid cell (intILC1) (CD49a+CD49b+Eomes+) populations and ILC1 (CD49a+CD49b−Eomesint) populations in the tumor microenvironment. Strikingly, intILC1s and ILC1s were unable to control local tumor growth and metastasis, whereas NK cells favored tumor immunosurveillance. Experiments with an antibody that neutralizes the cytokine TNF suggested that escape from the innate immune system was partially mediated by TNF-producing ILC1s. Our findings provide new insight into the plasticity of group 1 ILCs in the tumor microenvironment and suggest that the TGF-β-driven conversion of NK cells into ILC1s is a previously unknown mechanism by which tumors escape surveillance by the innate immune system.


Proceedings of the National Academy of Sciences of the United States of America | 2015

NK cells require IL-28R for optimal in vivo activity

Fernando Souza-Fonseca-Guimaraes; Arabella Young; Deepak Mittal; Ludovic Martinet; Claudia Bruedigam; Kazuyoshi Takeda; Christopher E. Andoniou; Mariapia A. Degli-Esposti; Geoffrey R. Hill; Mark J. Smyth

Significance Natural killer (NK) cells are naturally circulating innate lymphocytes that sense altered cells, including pathogen-activated and early-transformed cells. The signals that prime the NK cell to respond are not completely understood, but cytokines, such as IL-12, IL-18, and type I interferon (IFN-αβ) from antigen-presenting cells, are appreciated to be key to NK cell effector functions in response to bacteria, viruses, and tumors. In this light, another class of IFN, IFN type III (IFN-λ), has been described that shares some common functions with IFN-αβ, but with a more restricted cellular expression. Here, we demonstrate for the first time, to our knowledge, the ability of IFN-λ to directly regulate NK cell effector functions in vivo, alone and in the context of IFN-αβ. Natural killer (NK) cells are naturally circulating innate lymphoid cells that protect against tumor initiation and metastasis and contribute to immunopathology during inflammation. The signals that prime NK cells are not completely understood, and, although the importance of IFN type I is well recognized, the role of type III IFN is comparatively very poorly studied. IL-28R–deficient mice were resistant to LPS and cecal ligation puncture-induced septic shock, and hallmark cytokines in these disease models were dysregulated in the absence of IL-28R. IL-28R–deficient mice were more sensitive to experimental tumor metastasis and carcinogen-induced tumor formation than WT mice, and additional blockade of interferon alpha/beta receptor 1 (IFNAR1), but not IFN-γ, further enhanced metastasis and tumor development. IL-28R–deficient mice were also more susceptible to growth of the NK cell-sensitive lymphoma, RMAs. Specific loss of IL-28R in NK cells transferred into lymphocyte-deficient mice resulted in reduced LPS-induced IFN-γ levels and enhanced tumor metastasis. Therefore, by using IL-28R–deficient mice, which are unable to signal type III IFN-λ, we demonstrate for the first time, to our knowledge, the ability of IFN-λ to directly regulate NK cell effector functions in vivo, alone and in the context of IFN-αβ.


Immunology and Cell Biology | 2015

CD3 bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1 + T cells

Christophe Paget; Melvyn T. Chow; Nicholas A. Gherardin; Paul A. Beavis; Adam P. Uldrich; Helene Duret; Maya Hassane; Fernando Souza-Fonseca-Guimaraes; Denis Mogilenko; Delphine Staumont-Sallé; N K Escalante; Geoffrey R. Hill; Paul Neeson; David Ritchie; David Dombrowicz; Thierry Mallevaey; François Trottein; Gabrielle T. Belz; Dale I. Godfrey; Mark J. Smyth

Interleukin‐17A (IL‐17A) is a pro‐inflammatory cytokine that has an important role at mucosal sites in a wide range of immune responses including infection, allergy and auto‐immunity. γδ T cells are recognized as IL‐17 producers, but based on the level of CD3 expression, we now define the remarkable ability of a CD3bright γδ T‐cell subset with an effector memory phenotype to rapidly produce IL‐17A, but not interferon‐γ. CD3bright γδ T cells uniformly express the canonical germline encoded Vγ6/Vδ1+ T‐cell receptor. They are widely distributed with a preferential representation in the lungs and skin are negatively impacted in the absence of retinoic acid receptor‐related orphan receptor gammat expression or endogenous flora. This population responded rapidly to various stimuli in a mechanism involving IL‐23 and NOD‐like receptor family, pyrin domain containing 3 (NLRP3)‐inflammasome‐dependent IL‐1β. Finally, we demonstrated that IL‐17‐producing CD3bright γδ T cells responded promptly and strongly to pneumococcal infection and during skin inflammation. Here, we propose a new way to specifically analyze IL‐17‐producing Vγ6/Vδ1+ T cells based on the level of CD3 signals. Using this gating strategy, our data reinforce the crucial role of this γδ T‐cell subset in respiratory and skin disorders.


Clinical Immunology | 2017

Bench to bedside: NK cells and control of metastasis

Yelena Krasnova; Eva M. Putz; Mark J. Smyth; Fernando Souza-Fonseca-Guimaraes

Natural killer (NK) cells play a critical role in host immune responses against tumor growth and metastasis. The numerous mechanisms used by NK cells to regulate and control cancer metastasis include interactions with tumor cells via specific receptors and ligands as well as direct cytotoxicity and cytokine-induced effector mechanisms. NK cells also play a role in tumor immunosurveillance and inhibition of metastases formation by recognition and killing of tumor cells. In this review, we provide an overview of the molecular mechanisms of NK cell responses against tumor metastases and discuss multiple strategies by which tumors evade NK cell-mediated surveillance. With an increasing understanding of the molecular mechanisms driving NK cell activity, there is a growing potential for the development of new cancer immunotherapies. Here we provide a historical background on NK cell-based therapies and discuss the implications of recent and ongoing clinical trials using novel NK cell-based immunotherapy.


PLOS Pathogens | 2016

IFNAR1-Signalling Obstructs ICOS-mediated Humoral Immunity during Non-lethal Blood-Stage Plasmodium Infection

Ismail Sebina; Kylie R. James; Megan S. F. Soon; Lily G. Fogg; Shannon E. Best; Fabian de Labastida Rivera; Marcela Montes de Oca; Fiona H. Amante; Bryce S. Thomas; Lynette Beattie; Fernando Souza-Fonseca-Guimaraes; Mark J. Smyth; Paul J. Hertzog; Geoffrey R. Hill; Andreas Hutloff; Christian R. Engwerda; Ashraful Haque

Parasite-specific antibodies protect against blood-stage Plasmodium infection. However, in malaria-endemic regions, it takes many months for naturally-exposed individuals to develop robust humoral immunity. Explanations for this have focused on antigenic variation by Plasmodium, but have considered less whether host production of parasite-specific antibody is sub-optimal. In particular, it is unclear whether host immune factors might limit antibody responses. Here, we explored the effect of Type I Interferon signalling via IFNAR1 on CD4+ T-cell and B-cell responses in two non-lethal murine models of malaria, P. chabaudi chabaudi AS (PcAS) and P. yoelii 17XNL (Py17XNL) infection. Firstly, we demonstrated that CD4+ T-cells and ICOS-signalling were crucial for generating germinal centre (GC) B-cells, plasmablasts and parasite-specific antibodies, and likewise that T follicular helper (Tfh) cell responses relied on B cells. Next, we found that IFNAR1-signalling impeded the resolution of non-lethal blood-stage infection, which was associated with impaired production of parasite-specific IgM and several IgG sub-classes. Consistent with this, GC B-cell formation, Ig-class switching, plasmablast and Tfh differentiation were all impaired by IFNAR1-signalling. IFNAR1-signalling proceeded via conventional dendritic cells, and acted early by limiting activation, proliferation and ICOS expression by CD4+ T-cells, by restricting the localization of activated CD4+ T-cells adjacent to and within B-cell areas of the spleen, and by simultaneously suppressing Th1 and Tfh responses. Finally, IFNAR1-deficiency accelerated humoral immune responses and parasite control by boosting ICOS-signalling. Thus, we provide evidence of a host innate cytokine response that impedes the onset of humoral immunity during experimental malaria.


JCI insight | 2016

Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease

Laetitia Le Texier; Katie E. Lineburg; Benjamin Cao; Cameron McDonald-Hyman; Lucie Leveque-El Mouttie; Jemma Nicholls; Michelle Melino; Blessy C. Nalkurthi; Kylie A. Alexander; Bianca E. Teal; Stephen J. Blake; Fernando Souza-Fonseca-Guimaraes; Christian R. Engwerda; Rachel D. Kuns; Steven W. Lane; Michele Teng; Charis E. Teh; Daniel Gray; Andrew D. Clouston; Susan K. Nilsson; Bruce R. Blazar; Geoffrey R. Hill; Kelli P. A. MacDonald

Regulatory T cells (Tregs) play a crucial role in the maintenance of peripheral tolerance. Quantitative and/or qualitative defects in Tregs result in diseases such as autoimmunity, allergy, malignancy, and graft-versus-host disease (GVHD), a serious complication of allogeneic stem cell transplantation (SCT). We recently reported increased expression of autophagy-related genes (Atg) in association with enhanced survival of Tregs after SCT. Autophagy is a self-degradative process for cytosolic components that promotes cell homeostasis and survival. Here, we demonstrate that the disruption of autophagy within FoxP3+ Tregs (B6.Atg7fl/fl-FoxP3cre+ ) resulted in a profound loss of Tregs, particularly within the bone marrow (BM). This resulted in dysregulated effector T cell activation and expansion, and the development of enterocolitis and scleroderma in aged mice. We show that the BM compartment is highly enriched in TIGIT+ Tregs and that this subset is differentially depleted in the absence of autophagy. Moreover, following allogeneic SCT, recipients of grafts from B6.Atg7fl/fl-FoxP3cre+ donors exhibited reduced Treg reconstitution, exacerbated GVHD, and reduced survival compared with recipients of B6.WT-FoxP3cre+ grafts. Collectively, these data indicate that autophagy-dependent Tregs are critical for the maintenance of tolerance after SCT and that the promotion of autophagy represents an attractive immune-restorative therapeutic strategy after allogeneic SCT.


Blood | 2017

GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity

Mark D. Bunting; Antiopi Varelias; Fernando Souza-Fonseca-Guimaraes; Iona S. Schuster; Katie E. Lineburg; Rachel D. Kuns; Peter Fleming; Kelly R. Locke; Nicholas D. Huntington; Bruce R. Blazar; Steven W. Lane; Siok-Keen Tey; Kelli P. A. MacDonald; Mark J. Smyth; Mariapia A. Degli-Esposti; Geoffrey R. Hill

Allogeneic bone marrow transplantation (allo-BMT) is a curative therapy for hematological malignancies, but is associated with significant complications, principally graft-versus-host disease (GVHD) and opportunistic infections. Natural killer (NK) cells mediate important innate immunity that provides a temporal bridge until the reconstruction of adaptive immunity. Here, we show that the development of GVHD after allo-BMT prevented NK-cell reconstitution, particularly within the maturing M1 and M2 NK-cell subsets in association with exaggerated activation, apoptosis, and autophagy. Donor T cells were critical in this process by limiting the availability of interleukin 15 (IL-15), and administration of IL-15/IL-15Rα or immune suppression with rapamycin could restore NK-cell reconstitution. Importantly, the NK-cell defect induced by GVHD resulted in the failure of NK-cell-dependent in vivo cytotoxicity and graft-versus-leukemia effects. Control of cytomegalovirus infection after allo-BMT was also impaired during GVHD. Thus, during GVHD, donor T cells compete with NK cells for IL-15 thereby inducing profound defects in NK-cell reconstitution that compromise both leukemia and pathogen-specific immunity.


Journal of Experimental Medicine | 2017

Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival

Charlotte Viant; Sophie Guia; Robert J. Hennessy; Jai Rautela; Kim Pham; Claire Bernat; Wilford Goh; Yuhao Jiao; Rebecca B. Delconte; Michael Roger; Vanina Simon; Fernando Souza-Fonseca-Guimaraes; Stephanie Grabow; Gabrielle T. Belz; Benjamin T. Kile; Andreas Strasser; Daniel Gray; Phillip D. Hodgkin; Bruce Beutler; Eric Vivier; Sophie Ugolini; Nicholas D. Huntington

Natural killer (NK) cells are innate lymphoid cells with antitumor functions. Using an N-ethyl-N-nitrosourea (ENU)–induced mutagenesis screen in mice, we identified a strain with an NK cell deficiency caused by a hypomorphic mutation in the Bcl2 (B cell lymphoma 2) gene. Analysis of these mice and the conditional deletion of Bcl2 in NK cells revealed a nonredundant intrinsic requirement for BCL2 in NK cell survival. In these mice, NK cells in cycle were protected against apoptosis, and NK cell counts were restored in inflammatory conditions, suggesting a redundant role for BCL2 in proliferating NK cells. Consistent with this, cycling NK cells expressed higher MCL1 (myeloid cell leukemia 1) levels in both control and BCL2-null mice. Finally, we showed that deletion of BIM restored survival in BCL2-deficient but not MCL1-deficient NK cells. Overall, these data demonstrate an essential role for the binding of BCL2 to BIM in the survival of noncycling NK cells. They also favor a model in which MCL1 is the dominant survival protein in proliferating NK cells.


Cancer Research | 2017

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment

Arabella Young; Shin Foong Ngiow; Yulong Gao; Ann Marie Patch; Deborah S. Barkauskas; Meriem Messaoudene; Gene Lin; Jérôme D. Coudert; Kimberley Stannard; Laurence Zitvogel; Mariapia A. Degli-Esposti; Eric Vivier; Nicola Waddell; Joel Linden; Nicholas D. Huntington; Fernando Souza-Fonseca-Guimaraes; Mark J. Smyth

Extracellular adenosine is a key immunosuppressive metabolite that restricts activation of cytotoxic lymphocytes and impairs antitumor immune responses. Here, we show that engagement of A2A adenosine receptor (A2AR) acts as a checkpoint that limits the maturation of natural killer (NK) cells. Both global and NK-cell-specific conditional deletion of A2AR enhanced proportions of terminally mature NK cells at homeostasis, following reconstitution, and in the tumor microenvironment. Notably, A2AR-deficient, terminally mature NK cells retained proliferative capacity and exhibited heightened reconstitution in competitive transfer assays. Moreover, targeting A2AR specifically on NK cells also improved tumor control and delayed tumor initiation. Taken together, our results establish A2AR-mediated adenosine signaling as an intrinsic negative regulator of NK-cell maturation and antitumor immune responses. On the basis of these findings, we propose that administering A2AR antagonists concurrently with NK cell-based therapies may heighten therapeutic benefits by augmenting NK cell-mediated antitumor immunity.Significance: Ablating adenosine signaling is found to promote natural killer cell maturation and antitumor immunity and reduce tumor growth. Cancer Res; 78(4); 1003-16. ©2017 AACR.

Collaboration


Dive into the Fernando Souza-Fonseca-Guimaraes's collaboration.

Top Co-Authors

Avatar

Mark J. Smyth

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Nicholas D. Huntington

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Christian R. Engwerda

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Gabrielle T. Belz

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Geoffrey R. Hill

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Jai Rautela

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Rebecca B. Delconte

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Eric Vivier

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar

Arabella Young

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Kelli P. A. MacDonald

QIMR Berghofer Medical Research Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge